; onclick=)
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/gilteritinib-uses-dosage-side-effects-interaction_245746.jpg?fit=800%2C600&ssl=1" class="aligncenter wp-post-image" alt="" decoding="async" srcset="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/gilteritinib-uses-dosage-side-effects-interaction_245746.jpg?w=800&ssl=1 800w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/gilteritinib-uses-dosage-side-effects-interaction_245746.jpg?resize=768%2C576&ssl=1 768w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/gilteritinib-uses-dosage-side-effects-interaction_245746.jpg?resize=360%2C270&ssl=1 360w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/gilteritinib-uses-dosage-side-effects-interaction_245746.jpg?resize=600%2C450&ssl=1 600w" sizes="(max-width: 800px) 100vw, 800px" data-attachment-id="255559" data-permalink="https://rxharun.com/rxharun/drug-a-z/gilteritinib/attachment/gilteritinib-uses-dosage-side-effects-interaction/" data-orig-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/gilteritinib-uses-dosage-side-effects-interaction_245746.jpg?fit=800%2C600&ssl=1" data-orig-size="800,600" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Gilteritinib – Uses, Dosage, Side Effects, Interaction" data-image-description="" data-image-caption="" data-medium-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/gilteritinib-uses-dosage-side-effects-interaction_245746.jpg?fit=800%2C600&ssl=1" data-large-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/gilteritinib-uses-dosage-side-effects-interaction_245746.jpg?fit=800%2C600&ssl=1" data-jpibfi-post-excerpt="" data-jpibfi-post-url="https://rxharun.com/rxharun/drug-a-z/gilteritinib/" data-jpibfi-post-title="Gilteritinib – Uses, Dosage, Side Effects, Interaction" data-jpibfi-src="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/gilteritinib-uses-dosage-side-effects-interaction_245746.jpg?fit=800%2C600&ssl=1">
Gilteritinib is an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK, and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.
Gilteritinib is an orally available small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3) which is used as an antineoplastic agent in the treatment of acute myeloid leukemia with FLT3 mutations. Gilteritinib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to cause rare instances of clinically apparent acute liver injury.
Gilteritinib is a member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have an FLT3 gene mutation. It has a role as an apoptosis inducer, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, and an antineoplastic agent. It is an N-methyl piperazine, a member of piperidines, a secondary amino compound, a monomethoxybenzene, a member of pyrazines, a primary carboxamide, an aromatic amine, and a member of oxanes.
Gilteritinib Fumarate is the fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK, and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group.[rx] It is a pyrazine carboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.[rx] Gilteritinib was developed by Astellas Pharma and FDA-approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.[rx]
Mechanism of Action
Gilteritinib is a potent selective inhibitor of both of the mutations, internal tandem duplication (ITD) and tyrosine kinase domain (TKD), of the FLT3 receptor. On the same note, gilteritinib also inhibits AXL and ALK tyrosine kinases. FLT3 and AXL are molecules involved in the growth of cancer cells. The activity of gilteritinib permits inhibition of the phosphorylation of FLT3 and its downstream targets such as STAT5, ERK, and AKT. The interest in FLT3 transmembrane tyrosine kinases was raised when studies reported that approximately 30% of the patients with acute myeloid leukemia presented a mutationally activated isoform. As well, the mutation ITD is associated with poor patient outcomes while the mutation TKD produces a resistance mechanism to FLT3 tyrosine kinase inhibitors and the AXL tyrosine kinase tends to produce a resistance mechanism to chemotherapies.
In preclinical trials, gilteritinib demonstrate an IC50 for the wild-type receptor of 5 nM, 0.7-1.8 nM for ITD-mutated, and comparable inhibition to other therapies in the TKD-mutated. As well, data showed a gilteritinib-driven inhibition of the receptor tyrosine kinase AXL which is known to modulate the activity of FLT3 in acute myeloid leukemia. Another important result _in vivo_ was the localization in high levels in xenografted tumors which indicated high selectivity. In phase 1/2 clinical trials, gilteritinib was shown to present a composite complete response of 41%, an overall response rate of 52%, a median duration of response of 20 weeks with a median overall survival of 31 weeks. In phase III clinical trials, gilteritinib reported a complete remission or complete remission with partial hematologic recovery in 21% of the patients.
Indications
- Gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with an FLT3 mutation detected by an FDA-approved test. This indication was expanded for a companion diagnostic to include use with gilteritinib such as the LeukoStrat CDx FLT3 Mutation Assay. Acute myeloid leukemia is a cancer that impacts the blood and bone marrow with a rapid progression. This condition produces low numbers of normal blood cells and the requirement of a continuous need for transfusions.
- Gilteritinib is an AXL receptor tyrosine kinase inhibitor used to treat relapsed or refractory acute myeloid leukemia.
- Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.
- Gilteritinib is an orally available small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3) which is used as an antineoplastic agent in the treatment of acute myeloid leukemia with FLT3 mutations.
- Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.
- For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation.
Acute myeloid leukemia is cancer that impacts the blood and bone marrow with a rapid progression. This condition produces low numbers of normal blood cells and the requirement of continuous need for transfusions
Use in Cancer
Gilteritinib fumarate is approved to treat:
- Acute myeloid leukemia that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults whose cancer has a mutation in the FLT3 gene.
Gilteritinib fumarate is also being studied in the treatment of other types of cancer.
Contraindications
- Hypersensitivity to the active component or any of the ingredients
- Safety and efficacy have not been established in patients younger than 18 years.
- low amount of magnesium in the blood
- low amount of potassium in the blood
- prolonged QT interval on EKG
- abnormal EKG with QT changes from birth
- pregnancy
- a patient who is producing milk and breastfeeding
- pancreatitis
- a type of brain disorder called posterior reversible encephalopathy syndrome
Dosage
Strengths: 40 mg
Acute Myeloid Leukemia
- 120 mg orally once a day until disease progression or unacceptable toxicity
- The response may be delayed. In the absence of disease progression or unacceptable toxicity, patients should be treated for a minimum of 6 months to allow time for a clinical response.
- Select patients for the treatment of AML with this drug based on the presence of FLT3 mutations in the blood or bone marrow.
Dose Adjustments
DOSAGE MODIFICATIONS FOR TOXICITY:
DIFFERENTIATION SYNDROME:
- If differentiation syndrome is suspected, administer systemic corticosteroids and initiate hemodynamic monitoring until symptom resolution and for a minimum of 3 days.
- Interrupt therapy if severe symptoms persist for more than 48 hours after initiation of corticosteroids.
- Resume therapy when symptoms improve to Grade 2 or lower.
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME:
- Discontinue therapy.
QTc INTERVAL GREATER THAN 500 MSEC:
- Interrupt therapy; resume therapy at 80 mg orally once a day when QTc interval returns to within 30 msec of baseline or less than or equal to 480 msec.
QTc INTERVAL INCREASED BY MORE THAN 30 MSEC ON ECG ON DAY 8 OF CYCLE 1:
- Confirm with ECG on Day 9; if confirmed, consider dose reduction to 80 mg orally once a day.
- Interrupt therapy until pancreatitis is resolved; resume therapy at 80 mg orally once a day.
OTHER GRADE 3 OR HIGHER TOXICITY CONSIDERED RELATED TO TREATMENT:
- Interrupt therapy until toxicity resolves to Grade 1; resume therapy at 80 mg orally once a day.
Administration advice:
- Do not break or crush tablets.
- This drug may be taken with or without food.
- Administer this drug at approximately the same time each day.
- If a dose is missed or not taken at the usual time, administer it as soon as possible on the same day, and at least 12 hours prior to the next scheduled dose; return to normal schedule the following day.
- Do not administer 2 doses within 12 hours.
Side Effects
The Most Common
- joint or muscle pain
- extreme tiredness
- nausea
- vomiting
- diarrhea
- mouth sores
- change in the ability to taste food
- headache
- loss of appetite
- difficulty falling asleep or staying asleep
- seizures; headache; decreased alertness; confusion; or vision changes
- fast, pounding, or irregular heartbeat; fainting; loss of consciousness; or seizures
- ongoing pain that begins in the stomach area but may spread to the back that may occur with or without nausea and vomiting
More common
- Bloody urine
- blurred vision
- chest pain or tightness
- chills
- confusion
- cough
- decreased frequency or amount of urine
- dizziness
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- fainting
- fast or irregular heartbeat
- fever
- headache
- increased thirst
- lightheadedness
- loss of appetite
- lower back or side pain
- nausea
- nervousness
- pounding in the ears
- rapid, shallow breathing
- recurrent fainting
- slow heartbeat
- sneezing
- sore throat
- stomach pain
- sweating
- swelling of the face, fingers, or lower legs
- trouble breathing
- unusual tiredness or weakness
- vomiting
- weight gain
Rare
- Anxiety
- blue or pale skin
- chest discomfort
- chest pain, possibly moving to the left arm, neck, or shoulder
- difficulty swallowing
- the action of the mouth
- trouble sleeping
- stomach pain
- painting
- fever
- fluid build-up around the lungs (e.g., chest pain, cough, hiccups, rapid breathing)
- increased frequency or severity of infections (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
- inflammation of the mouth and lips
- low magnesium levels in the blood (e.g., weakness, tremors, muscle cramps, seizures)
- low potassium levels in the blood (e.g., weakness, fatigue, muscle cramps, irregular heartbeat)
- pain, numbness, or weakness in the hands and feet
- signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
- signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding)
- signs of heart problems (e.g., fast, irregular heartbeat or pulse; chest pain; sudden weight gain; difficulty breathing; leg swelling)
- signs of kidney failure (e.g., decreased urine production, swelling, fatigue, abdominal pain)
- signs of kidney problems (e.g., change in the amount or color of urine, increased urination at night, blood in the urine, swelling in the feet or legs)
- symptoms of high blood sugar (e.g., frequent urination, increased thirst, excessive eating, unexplained weight loss, poor wound healing, infections, fruity breath odor)
- swelling in the feet, ankles, hands
- vomiting, weakness
- shortness of breath
- fluid build-up around the heart (e.g., fever, fatigue, muscle aches, shortness of breath, nausea, vomiting, diarrhea, fast or pounding heartbeat, light-headedness)
- signs of an allergic reaction (e.g., wheezing, tightness in chest, troubled breathing, shortness of breath, or cough)
- signs of posterior reversible encephalopathy syndrome (e.g., headache, seizures, weakness, confusion, high blood pressure, vision changes, difficulty thinking clearly
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| Abaloparatide | The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Gilteritinib. |
| Abametapir | The serum concentration of Gilteritinib can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Gilteritinib can be increased when combined with Abatacept. |
| Abemaciclib | The excretion of Abemaciclib can be decreased when combined with Gilteritinib. |
| Abrocitinib | The serum concentration of Gilteritinib can be increased when it is combined with Abrocitinib. |
| Acalabrutinib | The metabolism of Acalabrutinib can be decreased when combined with Gilteritinib. |
| Acenocoumarol | The metabolism of Acenocoumarol can be decreased when combined with Gilteritinib. |
| Acetaminophen | The serum concentration of Acetaminophen can be increased when it is combined with Gilteritinib. |
| Acetazolamide | The metabolism of Gilteritinib can be decreased when combined with Acetazolamide. |
| Acetylcholine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Acetylcholine. |
| Acrivastine | The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Gilteritinib. |
| Acyclovir | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Acyclovir. |
| Adalimumab | The metabolism of Gilteritinib can be increased when combined with Adalimumab. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Gilteritinib. |
| Afatinib | Gilteritinib may decrease the excretion rate of Afatinib which could result in a higher serum level. |
| Agomelatine | The therapeutic efficacy of Agomelatine can be decreased when used in combination with Gilteritinib. |
| Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Gilteritinib. |
| Albendazole | The metabolism of Gilteritinib can be decreased when combined with Albendazole. |
| Aldesleukin | The metabolism of Gilteritinib can be decreased when combined with Aldesleukin. |
| Alectinib | The metabolism of Alectinib can be decreased when combined with Gilteritinib. |
| Alfuzosin | The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Gilteritinib. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Gilteritinib. |
| Allopurinol | Gilteritinib may decrease the excretion rate of Allopurinol which could result in a higher serum level. |
| Almotriptan | The therapeutic efficacy of Almotriptan can be decreased when used in combination with Gilteritinib. |
| Alosetron | The therapeutic efficacy of Alosetron can be decreased when used in combination with Gilteritinib. |
| Alpelisib | The serum concentration of Alpelisib can be increased when it is combined with Gilteritinib. |
| Alverine | The therapeutic efficacy of Alverine can be decreased when used in combination with Gilteritinib. |
| Amantadine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Amantadine. |
| Ambrisentan | The serum concentration of Gilteritinib can be increased when it is combined with Ambrisentan. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Gilteritinib. |
| Aminoglutethimide | The metabolism of Gilteritinib can be increased when combined with Aminoglutethimide. |
| Aminophylline | The metabolism of Aminophylline can be decreased when combined with Gilteritinib. |
| Amiodarone | The metabolism of Gilteritinib can be decreased when combined with Amiodarone. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Amisulpride. |
| Amitriptyline | The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Gilteritinib. |
| Amobarbital | The metabolism of Gilteritinib can be increased when combined with Amobarbital. |
| Amodiaquine | The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Gilteritinib. |
| Amoxapine | The therapeutic efficacy of Amoxapine can be decreased when used in combination with Gilteritinib. |
| Amprenavir | The metabolism of Gilteritinib can be decreased when combined with Amprenavir. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Anagrelide. |
| Anakinra | The metabolism of Gilteritinib can be increased when combined with Anakinra. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Antazoline is combined with Gilteritinib. |
| Apalutamide | The serum concentration of Gilteritinib can be decreased when it is combined with Apalutamide. |
| Apixaban | Gilteritinib may decrease the excretion rate of Apixaban which could result in a higher serum level. |
| Apomorphine | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Gilteritinib. |
| Apremilast | The metabolism of Gilteritinib can be increased when combined with Apremilast. |
| Aprepitant | The metabolism of Gilteritinib can be decreased when combined with Aprepitant. |
| Arformoterol | The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Gilteritinib. |
| Aripiprazole | The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Gilteritinib. |
| Aripiprazole | The therapeutic efficacy of Aripiprazole lauroxil can be decreased when used in combination with Gilteritinib. |
| Armodafinil | The metabolism of Gilteritinib can be increased when combined with Armodafinil. |
| Arsenic trioxide | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Arsenic trioxide. |
| Artemether | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Artemether. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Articaine. |
| Asciminib | The serum concentration of Gilteritinib can be increased when it is combined with Asciminib. |
| Asenapine | The therapeutic efficacy of Asenapine can be decreased when used in combination with Gilteritinib. |
| Astemizole | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Astemizole. |
| Asunaprevir | The serum concentration of Gilteritinib can be increased when it is combined with Asunaprevir. |
| Atazanavir | The metabolism of Gilteritinib can be decreased when combined with Atazanavir. |
| Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Gilteritinib. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Gilteritinib. |
| Avacopan | The metabolism of Gilteritinib can be decreased when combined with Avacopan. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Gilteritinib. |
| Avatrombopag | The serum concentration of Gilteritinib can be increased when it is combined with Avatrombopag. |
| Axitinib | The metabolism of Axitinib can be decreased when combined with Gilteritinib. |
| Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Gilteritinib. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Gilteritinib. |
| Beclomethasone | The metabolism of Gilteritinib can be increased when combined with Beclomethasone dipropionate. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Gilteritinib. |
| Belantamab | The serum concentration of Belantamab mafodotin can be increased when it is combined with Gilteritinib. |
| Belinostat | The serum concentration of Gilteritinib can be increased when it is combined with Belinostat. |
| Belumosudil | The serum concentration of Gilteritinib can be increased when it is combined with Belumosudil. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Gilteritinib. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Gilteritinib. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Benzyl alcohol. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Bepridil. |
| Berotralstat | The serum concentration of Berotralstat can be increased when it is combined with Gilteritinib. |
| Betamethasone | The metabolism of Gilteritinib can be increased when combined with Betamethasone. |
| Betamethasone | The metabolism of Gilteritinib can be increased when combined with Betamethasone phosphate. |
| Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Gilteritinib. |
| Bexarotene | The metabolism of Gilteritinib can be increased when combined with Bexarotene. |
| Bicalutamide | The metabolism of Bicalutamide can be decreased when combined with Gilteritinib. |
| Bifonazole | The metabolism of Gilteritinib can be decreased when combined with Bifonazole. |
| Bilastine | The risk or severity of QTc prolongation can be increased when Bilastine is combined with Gilteritinib. |
| Bimekizumab | The metabolism of Gilteritinib can be increased when combined with Bimekizumab. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Gilteritinib. |
| Bisoprolol | The serum concentration of Gilteritinib can be increased when it is combined with Bisoprolol. |
| Boceprevir | The metabolism of Gilteritinib can be decreased when combined with Boceprevir. |
| Bortezomib | The metabolism of Bortezomib can be decreased when combined with Gilteritinib. |
| Bosentan | The metabolism of Gilteritinib can be increased when combined with Bosentan. |
| Bosutinib | The metabolism of Bosutinib can be decreased when combined with Gilteritinib. |
| Brentuximab | The metabolism of Brentuximab vedotin can be decreased when combined with Gilteritinib. |
| Bretylium | The risk or severity of QTc prolongation can be increased when Bretylium is combined with Gilteritinib. |
| Brexpiprazole | The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Gilteritinib. |
| Brigatinib | The metabolism of Brigatinib can be decreased when combined with Gilteritinib. |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Gilteritinib. |
| Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Gilteritinib. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Gilteritinib. |
| Budesonide | The metabolism of Gilteritinib can be increased when combined with Budesonide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Bupivacaine. |
| Buprenorphine | The metabolism of Gilteritinib can be decreased when combined with Buprenorphine. |
| Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Gilteritinib. |
| Buspirone | The therapeutic efficacy of Buspirone can be decreased when used in combination with Gilteritinib. |
| Busulfan | The metabolism of Busulfan can be decreased when combined with Gilteritinib. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Butacaine. |
| Butalbital | The metabolism of Gilteritinib can be increased when combined with Butalbital. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Butamben. |
| Butriptyline | The therapeutic efficacy of Butriptyline can be decreased when used in combination with Gilteritinib. |
| Cabazitaxel | The metabolism of Cabazitaxel can be decreased when combined with Gilteritinib. |
| Cabergoline | The therapeutic efficacy of Cabergoline can be decreased when used in combination with Gilteritinib. |
| Calcitriol | The metabolism of Gilteritinib can be increased when combined with Calcitriol. |
| Canagliflozin | The serum concentration of Gilteritinib can be increased when it is combined with Canagliflozin. |
| Canakinumab | The metabolism of Gilteritinib can be increased when combined with Canakinumab. |
| Candicidin | The metabolism of Gilteritinib can be decreased when combined with Candicidin. |
| Cannabidiol | The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Gilteritinib. |
| Capmatinib | The serum concentration of Gilteritinib can be increased when it is combined with Capmatinib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Capsaicin. |
| Carbamazepine | The metabolism of Gilteritinib can be increased when combined with Carbamazepine. |
| Carbimazole | The therapeutic efficacy of Carbimazole can be decreased when used in combination with Gilteritinib. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Gilteritinib. |
| Carfilzomib | The serum concentration of Gilteritinib can be increased when it is combined with Carfilzomib. |
| Cariprazine | The therapeutic efficacy of Cariprazine can be decreased when used in combination with Gilteritinib. |
| Carvedilol | The serum concentration of Gilteritinib can be increased when it is combined with Carvedilol. |
| Cefradine | The metabolism of Gilteritinib can be increased when combined with Cefradine. |
| Celecoxib | Gilteritinib may decrease the excretion rate of Celecoxib which could result in a higher serum level. |
| Celiprolol | The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Gilteritinib. |
| Cenobamate | The serum concentration of Gilteritinib can be decreased when it is combined with Cenobamate. |
| Cephalexin | The metabolism of Gilteritinib can be decreased when combined with Cephalexin. |
| Ceritinib | The metabolism of Ceritinib can be decreased when combined with Gilteritinib. |
| Cerivastatin | Gilteritinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level. |
| Certolizumab | The metabolism of Gilteritinib can be increased when combined with Certolizumab pegol. |
| Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Gilteritinib. |
| Chloramphenicol | The metabolism of Gilteritinib can be decreased when combined with Chloramphenicol. |
| Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Gilteritinib. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Chloroprocaine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Gilteritinib. |
| Chlorpheniramine | The therapeutic efficacy of Chlorpheniramine can be decreased when used in combination with Gilteritinib. |
| Chlorpromazine | The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Gilteritinib. |
| Chlorprothixene | The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Gilteritinib. |
| Choline | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Choline. |
| Choline salicylate | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Choline salicylate. |
| Cilostazol | The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Gilteritinib. |
| Cimetidine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Cinchocaine. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Gilteritinib. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Gilteritinib. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Gilteritinib. |
| Cisapride | The therapeutic efficacy of Cisapride can be decreased when used in combination with Gilteritinib. |
| Citalopram | The therapeutic efficacy of Citalopram can be decreased when used in combination with Gilteritinib. |
| Cladribine | Gilteritinib may decrease the excretion rate of Cladribine which could result in a higher serum level. |
| Clarithromycin | The metabolism of Gilteritinib can be decreased when combined with Clarithromycin. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Clemastine. |
| Clevidipine | The metabolism of Gilteritinib can be increased when combined with Clevidipine. |
| Clobazam | The metabolism of Gilteritinib can be increased when combined with Clobazam. |
| Clobetasol | The metabolism of Gilteritinib can be increased when combined with Clobetasol propionate. |
| Clofarabine | Gilteritinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Clofazimine | The serum concentration of Gilteritinib can be increased when it is combined with Clofazimine. |
| Clofibrate | The metabolism of Gilteritinib can be increased when combined with Clofibrate. |
| Clomifene | The serum concentration of Gilteritinib can be increased when it is combined with Clomifene. |
| Clomipramine | The therapeutic efficacy of Clomipramine can be decreased when used in combination with Gilteritinib. |
| Clonidine | The metabolism of Clonidine can be decreased when combined with Gilteritinib. |
| Clozapine | The therapeutic efficacy of Clozapine can be decreased when used in combination with Gilteritinib. |
| Cobicistat | The metabolism of Gilteritinib can be decreased when combined with Cobicistat. |
| Cobimetinib | The metabolism of Cobimetinib can be decreased when combined with Gilteritinib. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Cocaine. |
| Codeine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Codeine. |
| Colchicine | The serum concentration of Gilteritinib can be increased when it is combined with Colchicine. |
| Conivaptan | The metabolism of Gilteritinib can be decreased when combined with Conivaptan. |
| Conjugated | Gilteritinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. |
| Copanlisib | The metabolism of Copanlisib can be decreased when combined with Gilteritinib. |
| Corticotropin | The metabolism of Gilteritinib can be increased when combined with Corticotropin. |
| Cortisone acetate | The metabolism of Gilteritinib can be increased when combined with Cortisone acetate. |
| Crizotinib | The metabolism of Crizotinib can be decreased when combined with Gilteritinib. |
| Curcumin | The metabolism of Gilteritinib can be decreased when combined with Curcumin. |
| Cyclizine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Gilteritinib. |
| Cyclobenzaprine | The therapeutic efficacy of Cyclobenzaprine can be decreased when used in combination with Gilteritinib. |
| Cyclophosphamide | The metabolism of Cyclophosphamide can be decreased when combined with Gilteritinib. |
| Cyclosporine | The metabolism of Cyclosporine can be decreased when combined with Gilteritinib. |
| Cyproheptadine | The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Gilteritinib. |
| Cyproterone | The metabolism of Gilteritinib can be decreased when combined with Cyproterone acetate. |
| Cytarabine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Cytarabine. |
| Dabigatran | The serum concentration of Gilteritinib can be increased when it is combined with Dabigatran etexilate. |
| Dabrafenib | The serum concentration of Gilteritinib can be decreased when it is combined with Dabrafenib. |
| Daclatasvir | The serum concentration of Gilteritinib can be increased when it is combined with Daclatasvir. |
| Dacomitinib | The metabolism of Dacomitinib can be decreased when combined with Gilteritinib. |
| Dactinomycin | Gilteritinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. |
| Dalfopristin | The metabolism of Gilteritinib can be decreased when combined with Dalfopristin. |
| Danazol | The metabolism of Gilteritinib can be decreased when combined with Danazol. |
| Daptomycin | The serum concentration of Gilteritinib can be increased when it is combined with Daptomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gilteritinib. |
| Darolutamide | Gilteritinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Darunavir | The metabolism of Gilteritinib can be decreased when combined with Darunavir. |
| Dasabuvir | The serum concentration of Gilteritinib can be increased when it is combined with Dasabuvir. |
| Dasatinib | The metabolism of Dasatinib can be decreased when combined with Gilteritinib. |
| Daunorubicin | Gilteritinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. |
| Deferasirox | The metabolism of Gilteritinib can be increased when combined with Deferasirox. |
| Deflazacort | The metabolism of Gilteritinib can be increased when combined with Deflazacort. |
| Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Gilteritinib. |
| Delafloxacin | Gilteritinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level. |
| Delamanid | Gilteritinib may increase the QTc-prolonging activities of Delamanid. |
| Delavirdine | The metabolism of Gilteritinib can be decreased when combined with Delavirdine. |
| Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Gilteritinib. |
| Desipramine | The therapeutic efficacy of Desipramine can be decreased when used in combination with Gilteritinib. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Gilteritinib. |
| Desvenlafaxine | The therapeutic efficacy of Desvenlafaxine can be decreased when used in combination with Gilteritinib. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Deutetrabenazine. |
| Dexamethasone | The metabolism of Gilteritinib can be increased when combined with Dexamethasone. |
| Dexamethasone | The metabolism of Gilteritinib can be increased when combined with Dexamethasone acetate. |
| Dexbromphenira | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Gilteritinib. |
| Dexchlorpheniram | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Gilteritinib. |
| Dexmethylphenid | The therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Gilteritinib. |
| Dextromethorphan | The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Gilteritinib. |
| Dextropropoxy | The metabolism of Gilteritinib can be decreased when combined with Dextropropoxyphene. |
| Dicloxacillin | The metabolism of Gilteritinib can be increased when combined with Dicloxacillin. |
| Diethylstilbestrol | The metabolism of Gilteritinib can be decreased when combined with Diethylstilbestrol. |
| Difluocortolone | The metabolism of Gilteritinib can be increased when combined with Difluocortolone. |
| Digitoxin | The metabolism of Digitoxin can be decreased when combined with Gilteritinib. |
| Digoxin | The serum concentration of Digoxin can be increased when it is combined with Gilteritinib. |
| Dihydroergocornine | The metabolism of Gilteritinib can be decreased when combined with Dihydroergocornine. |
| Dihydroergocristine | The metabolism of Dihydroergocristine can be decreased when combined with Gilteritinib. |
| Dihydroergotamine | The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Gilteritinib. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Gilteritinib. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Gilteritinib. |
| Dimethyl sulfoxide | The metabolism of Gilteritinib can be decreased when combined with Dimethyl sulfoxide. |
| Diosmin | The serum concentration of Gilteritinib can be increased when it is combined with Diosmin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Diphenhydramine. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Disopyramide. |
| Disulfiram | The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Gilteritinib. |
| Docetaxel | The metabolism of Docetaxel can be decreased when combined with Gilteritinib. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Dofetilide. |
| Dolasetron | The therapeutic efficacy of Dolasetron can be decreased when used in combination with Gilteritinib. |
| Dolutegravir | Gilteritinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Domperidone. |
| Donepezil | Gilteritinib may decrease the excretion rate of Donepezil which could result in a higher serum level. |
| Dopamine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Dopamine. |
| Dosulepin | The therapeutic efficacy of Dosulepin can be decreased when used in combination with Gilteritinib. |
| Doxazosin | The metabolism of Gilteritinib can be decreased when combined with Doxazosin. |
| Doxepin | The therapeutic efficacy of Doxepin can be decreased when used in combination with Gilteritinib. |
| Doxorubicin | The metabolism of Doxorubicin can be decreased when combined with Gilteritinib. |
| Doxylamine | The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Gilteritinib. |
| Dronedarone | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Dronedarone. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Gilteritinib. |
| Drospirenone | The metabolism of Gilteritinib can be decreased when combined with Drospirenone. |
| Duloxetine | The therapeutic efficacy of Duloxetine can be decreased when used in combination with Gilteritinib. |
| Duvelisib | Gilteritinib may decrease the excretion rate of Duvelisib which could result in a higher serum level. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Dyclonine. |
| Ebastine | The metabolism of Gilteritinib can be decreased when combined with Ebastine. |
| Echinacea | The metabolism of Gilteritinib can be increased when combined with Echinacea. |
| Edoxaban | The serum concentration of Gilteritinib can be increased when it is combined with Edoxaban. |
| Efavirenz | The metabolism of Gilteritinib can be decreased when combined with Efavirenz. |
| Elagolix | The serum concentration of Gilteritinib can be increased when it is combined with Elagolix. |
| Elbasvir | The serum concentration of Gilteritinib can be increased when it is combined with Elbasvir. |
| Eletriptan | The therapeutic efficacy of Eletriptan can be decreased when used in combination with Gilteritinib. |
| Elexacaftor | The metabolism of Elexacaftor can be decreased when combined with Gilteritinib. |
| Eliglustat | The serum concentration of Gilteritinib can be increased when it is combined with Eliglustat. |
| Elvitegravir | The metabolism of Gilteritinib can be decreased when combined with Elvitegravir. |
| Emapalumab | The metabolism of Gilteritinib can be increased when combined with Emapalumab. |
| Emedastine | The risk or severity of QTc prolongation can be increased when Emedastine is combined with Gilteritinib. |
| Emtricitabine | The excretion of Emtricitabine can be decreased when combined with Gilteritinib. |
| Enasidenib | The metabolism of Enasidenib can be decreased when combined with Gilteritinib. |
| Encainide | The risk or severity of QTc prolongation can be increased when Encainide is combined with Gilteritinib. |
| Encorafenib | The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Gilteritinib. |
| Enfortumab | The serum concentration of Enfortumab vedotin can be increased when it is combined with Gilteritinib. |
| Enoxacin | The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Gilteritinib. |
| Entrectinib | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Entrectinib. |
| Enzalutamide | The serum concentration of Gilteritinib can be decreased when it is combined with Enzalutamide. |
| Epinastine | The therapeutic efficacy of Epinastine can be decreased when used in combination with Gilteritinib. |
| Epinephrine | The metabolism of Gilteritinib can be decreased when combined with Epinephrine. |
| Erdafitinib | The serum concentration of Gilteritinib can be increased when it is combined with Erdafitinib. |
| Ergoloid mesylate | The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Gilteritinib. |
| Ergometrine | The therapeutic efficacy of Ergometrine can be decreased when used in combination with Gilteritinib. |
| Ergotamine | The therapeutic efficacy of Ergotamine can be decreased when used in combination with Gilteritinib. |
| Eribulin | The risk or severity of QTc prolongation can be increased when Eribulin is combined with Gilteritinib. |
| Erlotinib | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Erlotinib. |
| Ertugliflozin | Gilteritinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Gilteritinib. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gilteritinib. |
| Escitalopram | The therapeutic efficacy of Escitalopram can be decreased when used in combination with Gilteritinib. |
| Esketamine | The metabolism of Gilteritinib can be increased when combined with Esketamine. |
| Eslicarbazepine | The metabolism of Gilteritinib can be increased when combined with Eslicarbazepine. |
| Eslicarbazepine | The metabolism of Gilteritinib can be increased when combined with Eslicarbazepine acetate. |
| Esmolol | The risk or severity of QTc prolongation can be increased when Esmolol is combined with Gilteritinib. |
| Estetrol | The metabolism of Estetrol can be decreased when combined with Gilteritinib. |
| Estradiol acetate | The metabolism of Gilteritinib can be increased when combined with Estradiol acetate. |
| Estradiol benzoate | The metabolism of Gilteritinib can be increased when combined with Estradiol benzoate. |
| Estradiol cypionate | The metabolism of Gilteritinib can be increased when combined with Estradiol cypionate. |
| Estradiol | The metabolism of Gilteritinib can be increased when combined with Estradiol dienanthate. |
| Estradiol valerate | The metabolism of Gilteritinib can be increased when combined with Estradiol valerate. |
| Estrone sulfate | The excretion of Estrone sulfate can be decreased when combined with Gilteritinib. |
| Etanercept | The metabolism of Gilteritinib can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Gilteritinib can be decreased when combined with Ethambutol. |
| Ethanol | The metabolism of Gilteritinib can be increased when combined with Ethanol. |
| Ethosuximide | The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Gilteritinib. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Etidocaine. |
| Etoposide | The metabolism of Etoposide can be decreased when combined with Gilteritinib. |
| Etoricoxib | The metabolism of Gilteritinib can be decreased when combined with Etoricoxib. |
| Etravirine | The metabolism of Gilteritinib can be increased when combined with Etravirine. |
| Everolimus | The metabolism of Everolimus can be decreased when combined with Gilteritinib. |
| Ezetimibe | Gilteritinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. |
| Ezogabine | The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Gilteritinib. |
| Famotidine | The risk or severity of QTc prolongation can be increased when Famotidine is combined with Gilteritinib. |
| Favipiravir | The serum concentration of Gilteritinib can be increased when it is combined with Favipiravir. |
| Fedratinib | The serum concentration of Gilteritinib can be increased when it is combined with Fedratinib. |
| Felbamate | The metabolism of Gilteritinib can be increased when combined with Felbamate. |
| Felodipine | The risk or severity of QTc prolongation can be increased when Felodipine is combined with Gilteritinib. |
| Fenfluramine | The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Gilteritinib. |
| Fenofibrate | The metabolism of Gilteritinib can be decreased when combined with Fenofibrate. |
| Fentanyl | The therapeutic efficacy of Fentanyl can be decreased when used in combination with Gilteritinib. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Fexinidazole. |
| Fexofenadine | The serum concentration of Gilteritinib can be increased when it is combined with Fexofenadine. |
| Flecainide | The risk or severity of QTc prolongation can be increased when Flecainide is combined with Gilteritinib. |
| Flibanserin | The therapeutic efficacy of Flibanserin can be decreased when used in combination with Gilteritinib. |
| Flucloxacillin | The metabolism of Gilteritinib can be increased when combined with Flucloxacillin. |
| Fluconazole | The metabolism of Gilteritinib can be decreased when combined with Fluconazole. |
| Flunisolide | The metabolism of Gilteritinib can be increased when combined with Flunisolide. |
| Fluocinolone | The metabolism of Gilteritinib can be increased when combined with Fluocinolone acetonide. |
| Fluocinonide | The metabolism of Gilteritinib can be increased when combined with Fluocinonide. |
| Fluocortolone | The metabolism of Gilteritinib can be increased when combined with Fluocortolone. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Gilteritinib. |
| Fluoxetine | The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Gilteritinib. |
| Flupentixol | The therapeutic efficacy of Flupentixol can be decreased when used in combination with Gilteritinib. |
| Fluspirilene | The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Gilteritinib. |
| Fluticasone | The metabolism of Gilteritinib can be increased when combined with Fluticasone. |
| Fluticasone | The metabolism of Gilteritinib can be increased when combined with Fluticasone furoate. |
| Fluticasone | The metabolism of Gilteritinib can be decreased when combined with Fluticasone propionate. |
| Fluvoxamine | The therapeutic efficacy of Fluvoxamine can be decreased when used in combination with Gilteritinib. |
| Folic acid | Gilteritinib may decrease the excretion rate of Folic acid which could result in a higher serum level. |
| Follitropin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Gilteritinib. |
| Formestane | The metabolism of Gilteritinib can be increased when combined with Formestane. |
| Formoterol | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Formoterol. |
| Fosamprenavir | The metabolism of Gilteritinib can be decreased when combined with Fosamprenavir. |
| Fosaprepitant | The metabolism of Gilteritinib can be increased when combined with Fosaprepitant. |
| Foscarnet | The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Gilteritinib. |
| Fosnetupitant | The metabolism of Gilteritinib can be decreased when combined with Fosnetupitant. |
| Fosphenytoin | The metabolism of Gilteritinib can be increased when combined with Fosphenytoin. |
| Fostamatinib | The metabolism of Gilteritinib can be decreased when combined with Fostamatinib. |
| Fostemsavir | Gilteritinib may decrease the excretion rate of Fostemsavir which could result in a higher serum level. |
| Frovatriptan | The therapeutic efficacy of Frovatriptan can be decreased when used in combination with Gilteritinib. |
| Fusidic acid | The metabolism of Gilteritinib can be decreased when combined with Fusidic acid. |
| Futibatinib | The serum concentration of Futibatinib can be increased when it is combined with Gilteritinib. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Gilteritinib. |
| Galantamine | The risk or severity of QTc prolongation can be increased when Galantamine is combined with Gilteritinib. |
| Ganciclovir | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Ganciclovir. |
| Gatifloxacin | The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Gilteritinib. |
| Gefitinib | Gilteritinib may decrease the excretion rate of Gefitinib which could result in a higher serum level. |
| Gemcitabine | The serum concentration of Gemcitabine can be increased when it is combined with Gilteritinib. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Gilteritinib. |
| Ginkgo biloba | The metabolism of Gilteritinib can be decreased when combined with Ginkgo biloba. |
| Glasdegib | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Glasdegib. |
| Glecaprevir | Gilteritinib may decrease the excretion rate of Glecaprevir which could result in a higher serum level. |
| Glyburide | Gilteritinib may decrease the excretion rate of Glyburide which could result in a higher serum level. |
| Glycerol | The metabolism of Gilteritinib can be increased when combined with Glycerol phenylbutyrate. |
| Golimumab | The metabolism of Gilteritinib can be increased when combined with Golimumab. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gilteritinib. |
| Granisetron | The therapeutic efficacy of Granisetron can be decreased when used in combination with Gilteritinib. |
| Grazoprevir | The serum concentration of Gilteritinib can be increased when it is combined with Grazoprevir. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Grepafloxacin. |
| Griseofulvin | The metabolism of Gilteritinib can be increased when combined with Griseofulvin. |
| Guanfacine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Guanfacine. |
| Guanidine | The excretion of Guanidine can be decreased when combined with Gilteritinib. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Halofantrine. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Haloperidol. |
| Histamine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Histamine. |
| Histrelin | The risk or severity of QTc prolongation can be increased when Histrelin is combined with Gilteritinib. |
| Hydralazine | The metabolism of Gilteritinib can be decreased when combined with Hydralazine. |
| Hydrochlorothiazide | The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Gilteritinib. |
| Hydrocortamate | The metabolism of Gilteritinib can be increased when combined with Hydrocortamate. |
| Hydrocortisone | The metabolism of Gilteritinib can be increased when combined with Hydrocortisone. |
| Hydrocortisone | The metabolism of Gilteritinib can be increased when combined with Hydrocortisone acetate. |
| Hydrocortisone | The metabolism of Gilteritinib can be increased when combined with Hydrocortisone butyrate. |
| Hydrocortisone | The metabolism of Gilteritinib can be increased when combined with Hydrocortisone succinate. |
| Hydroxychloroq | The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Gilteritinib. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Hydroxyzine. |
| Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Gilteritinib. |
| Ibandronate | The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gilteritinib. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Ibutilide. |
| Idelalisib | The metabolism of Idelalisib can be decreased when combined with Gilteritinib. |
| Ifosfamide | The metabolism of Ifosfamide can be decreased when combined with Gilteritinib. |
| Iloperidone | The therapeutic efficacy of Iloperidone can be decreased when used in combination with Gilteritinib. |
| Imatinib | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Imatinib. |
| Imipramine | The therapeutic efficacy of Imipramine can be decreased when used in combination with Gilteritinib. |
| Indacaterol | The serum concentration of Gilteritinib can be increased when it is combined with Indacaterol. |
| Indapamide | The risk or severity of QTc prolongation can be increased when Indapamide is combined with Gilteritinib. |
| Indinavir | The metabolism of Gilteritinib can be decreased when combined with Indinavir. |
| Infigratinib | The metabolism of Gilteritinib can be decreased when combined with Infigratinib. |
| Infliximab | The metabolism of Gilteritinib can be increased when combined with Infliximab. |
| Inotersen | The risk or severity of QTc prolongation can be increased when Inotersen is combined with Gilteritinib. |
| Inotuzumab | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Gilteritinib. |
| Irbesartan | The metabolism of Gilteritinib can be decreased when combined with Irbesartan. |
| Irinotecan | The metabolism of Irinotecan can be decreased when combined with Gilteritinib. |
| Isavuconazole | The serum concentration of Gilteritinib can be increased when it is combined with Isavuconazole. |
| Isavuconazonium | The serum concentration of Gilteritinib can be increased when it is combined with Isavuconazonium. |
| Isocarboxazid | The therapeutic efficacy of Isocarboxazid can be decreased when used in combination with Gilteritinib. |
| Isoflurane | The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Gilteritinib. |
| Isoniazid | The metabolism of Gilteritinib can be decreased when combined with Isoniazid. |
| Isradipine | The metabolism of Gilteritinib can be decreased when combined with Isradipine. |
| Istradefylline | The serum concentration of Gilteritinib can be increased when it is combined with Istradefylline. |
| Itraconazole | The metabolism of Gilteritinib can be decreased when combined with Itraconazole. |
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Gilteritinib. |
| Ivacaftor | The serum concentration of Gilteritinib can be increased when it is combined with Ivacaftor. |
| Ivermectin | Gilteritinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. |
| Ivosidenib | The metabolism of Gilteritinib can be increased when combined with Ivosidenib. |
| Ixabepilone | The metabolism of Ixabepilone can be decreased when combined with Gilteritinib. |
| Ixazomib | The metabolism of Ixazomib can be decreased when combined with Gilteritinib. |
| Ketazolam | The metabolism of Gilteritinib can be decreased when combined with Ketazolam. |
| Ketoconazole | The metabolism of Gilteritinib can be decreased when combined with Ketoconazole. |
| Lacidipine | The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Gilteritinib. |
| Lacosamide | The metabolism of Gilteritinib can be decreased when combined with Lacosamide. |
| Lamivudine | Gilteritinib may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
| Lamotrigine | The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Gilteritinib. |
| Lanreotide | The metabolism of Gilteritinib can be decreased when combined with Lanreotide. |
| Lapatinib | The serum concentration of Gilteritinib can be increased when it is combined with Lapatinib. |
| Larotrectinib | The serum concentration of Larotrectinib can be increased when it is combined with Gilteritinib. |
| Lasmiditan | The therapeutic efficacy of Lasmiditan can be decreased when used in combination with Gilteritinib. |
| Ledipasvir | The serum concentration of Gilteritinib can be increased when it is combined with Ledipasvir. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Gilteritinib. |
| Leflunomide | Gilteritinib may decrease the excretion rate of Leflunomide which could result in a higher serum level. |
| Lemborexant | The serum concentration of Gilteritinib can be increased when it is combined with Lemborexant. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Gilteritinib. |
| Lesinurad | The metabolism of Gilteritinib can be increased when combined with Lesinurad. |
| Letermovir | The metabolism of Gilteritinib can be decreased when combined with Letermovir. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gilteritinib. |
| Levacetylmethadol | The metabolism of Levacetylmethadol can be decreased when combined with Gilteritinib. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Levobupivacaine. |
| Levocabastine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Gilteritinib. |
| Levocetirizine | The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Gilteritinib. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Gilteritinib. |
| Levoketoconazole | The metabolism of Gilteritinib can be decreased when combined with Levoketoconazole. |
| Levomenthol | The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Gilteritinib. |
| Levomilnacipran | The therapeutic efficacy of Levomilnacipran can be decreased when used in combination with Gilteritinib. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Gilteritinib. |
| Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Gilteritinib. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Lidocaine. |
| Lidoflazine | The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Gilteritinib. |
| Linagliptin | The metabolism of Gilteritinib can be decreased when combined with Linagliptin. |
| Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with Gilteritinib. |
| Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with Gilteritinib. |
| Lisuride | The therapeutic efficacy of Lisuride can be decreased when used in combination with Gilteritinib. |
| Lofexidine | The therapeutic efficacy of Lofexidine can be decreased when used in combination with Gilteritinib. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Gilteritinib. |
| Lomitapide | The metabolism of Lomitapide can be decreased when combined with Gilteritinib. |
| Lonafarnib | The metabolism of Gilteritinib can be decreased when combined with Lonafarnib. |
| Loncastuximab | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Gilteritinib. |
| Loperamide | The risk or severity of QTc prolongation can be increased when Loperamide is combined with Gilteritinib. |
| Lopinavir | The metabolism of Gilteritinib can be decreased when combined with Lopinavir. |
| Lorcaserin | The therapeutic efficacy of Lorcaserin can be decreased when used in combination with Gilteritinib. |
| Lorlatinib | The metabolism of Gilteritinib can be increased when combined with Lorlatinib. |
| Losartan | The metabolism of Gilteritinib can be decreased when combined with Losartan. |
| Lovastatin | The metabolism of Gilteritinib can be decreased when combined with Lovastatin. |
| Loxapine | The therapeutic efficacy of Loxapine can be decreased when used in combination with Gilteritinib. |
| Lumacaftor | The serum concentration of Gilteritinib can be decreased when it is combined with Lumacaftor. |
| Lumefantrine | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Lumefantrine. |
| Lurasidone | The therapeutic efficacy of Lurasidone can be decreased when used in combination with Gilteritinib. |
| Lusutrombopag | Gilteritinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. |
| Macimorelin | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Macimorelin. |
| Manidipine | The metabolism of Gilteritinib can be decreased when combined with Manidipine. |
| Mannitol | The serum concentration of Gilteritinib can be increased when it is combined with Mannitol. |
| Maprotiline | The therapeutic efficacy of Maprotiline can be decreased when used in combination with Gilteritinib. |
| Maribavir | The serum concentration of Gilteritinib can be increased when it is combined with Maribavir. |
| Mavacamten | The serum concentration of Gilteritinib can be decreased when it is combined with Mavacamten. |
| Mazindol | The therapeutic efficacy of Mazindol can be decreased when used in combination with Gilteritinib. |
| Medroxyproges | The metabolism of Gilteritinib can be increased when combined with Medroxyprogesterone acetate. |
| Mefloquine | The serum concentration of Gilteritinib can be increased when it is combined with Mefloquine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Meloxicam. |
| Meperidine | The therapeutic efficacy of Meperidine can be decreased when used in combination with Gilteritinib. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Mepivacaine. |
| Meprednisone | The metabolism of Gilteritinib can be increased when combined with Meprednisone. |
| Mepyramine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Gilteritinib. |
| Mesoridazine | The therapeutic efficacy of Mesoridazine can be decreased when used in combination with Gilteritinib. |
| Metergoline | The therapeutic efficacy of Metergoline can be decreased when used in combination with Gilteritinib. |
| Metformin | The excretion of Metformin can be decreased when combined with Gilteritinib. |
| Methadone | The therapeutic efficacy of Methadone can be decreased when used in combination with Gilteritinib. |
| Methimazole | The metabolism of Gilteritinib can be decreased when combined with Methimazole. |
| Methotrexate | The metabolism of Methotrexate can be decreased when combined with Gilteritinib. |
| Methotrimeprazine | The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Gilteritinib. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gilteritinib. |
| Methsuximide | The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Gilteritinib. |
| Methylene blue | The serum concentration of Gilteritinib can be increased when it is combined with Methylene blue. |
| Methylergometrine | The metabolism of Gilteritinib can be decreased when combined with Methylergometrine. |
| Methylphenobarbital | The metabolism of Gilteritinib can be increased when combined with Methylphenobarbital. |
| Methylprednisolone | The metabolism of Gilteritinib can be increased when combined with Methylprednisolone. |
| Methylprednisone | The metabolism of Methylprednisone can be decreased when combined with Gilteritinib. |
| Methysergide | The therapeutic efficacy of Methysergide can be decreased when used in combination with Gilteritinib. |
| Metoclopramide | The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Gilteritinib. |
| Metreleptin | The metabolism of Gilteritinib can be increased when combined with Metreleptin. |
| Metronidazole | The metabolism of Gilteritinib can be decreased when combined with Metronidazole. |
| Metyrapone | The metabolism of Gilteritinib can be increased when combined with Metyrapone. |
| Mianserin | The therapeutic efficacy of Mianserin can be decreased when used in combination with Gilteritinib. |
| Miconazole | The metabolism of Gilteritinib can be decreased when combined with Miconazole. |
| Midazolam | The metabolism of Gilteritinib can be decreased when combined with Midazolam. |
| Midostaurin | The metabolism of Gilteritinib can be decreased when combined with Midostaurin. |
| Mifepristone | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Mifepristone. |
| Milnacipran | The therapeutic efficacy of Milnacipran can be decreased when used in combination with Gilteritinib. |
| Miocamycin | The metabolism of Gilteritinib can be decreased when combined with Miocamycin. |
| Mirabegron | The serum concentration of Gilteritinib can be increased when it is combined with Mirabegron. |
| Mirtazapine | The therapeutic efficacy of Mirtazapine can be decreased when used in combination with Gilteritinib. |
| Mitapivat | The serum concentration of Gilteritinib can be increased when it is combined with Mitapivat. |
| Mitotane | The metabolism of Gilteritinib can be increased when combined with Mitotane. |
| Mitoxantrone | Gilteritinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. |
| Mizolastine | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Mizolastine. |
| Mobocertinib | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Mobocertinib. |
| Moclobemide | The therapeutic efficacy of Moclobemide can be decreased when used in combination with Gilteritinib. |
| Modafinil | The metabolism of Gilteritinib can be increased when combined with Modafinil. |
| Moexipril | The risk or severity of QTc prolongation can be increased when Moexipril is combined with Gilteritinib. |
| Molindone | The therapeutic efficacy of Molindone can be decreased when used in combination with Gilteritinib. |
| Mometasone | The metabolism of Gilteritinib can be increased when combined with Mometasone furoate. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Moricizine is combined with Gilteritinib. |
| Morphine | The serum concentration of Gilteritinib can be increased when it is combined with Morphine. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Gilteritinib. |
| Mycophenolate | Gilteritinib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. |
| Nadolol | The excretion of Nadolol can be decreased when combined with Gilteritinib. |
| Nafcillin | The metabolism of Gilteritinib can be increased when combined with Nafcillin. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Gilteritinib. |
| Naloxone | The metabolism of Gilteritinib can be decreased when combined with Naloxone. |
| Naratriptan | The therapeutic efficacy of Naratriptan can be decreased when used in combination with Gilteritinib. |
| Nefazodone | The therapeutic efficacy of Nefazodone can be decreased when used in combination with Gilteritinib. |
| Nelfinavir | The metabolism of Gilteritinib can be decreased when combined with Nelfinavir. |
| Neratinib | The metabolism of Neratinib can be decreased when combined with Gilteritinib. |
| Netupitant | The metabolism of Gilteritinib can be decreased when combined with Netupitant. |
| Niacin | The metabolism of Gilteritinib can be decreased when combined with Niacin. |
| Nicardipine | The metabolism of Gilteritinib can be decreased when combined with Nicardipine. |
| Nifedipine | The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Gilteritinib. |
| Nilotinib | The metabolism of Gilteritinib can be decreased when combined with Nilotinib. |
| Nilvadipine | The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Gilteritinib. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Gilteritinib. |
| Nintedanib | The metabolism of Gilteritinib can be decreased when combined with Nintedanib. |
| Nitrendipine | The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Gilteritinib. |
| Nitrofurantoin | Gilteritinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
| Norepinephrine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Norepinephrine. |
| Norethisterone | The metabolism of Gilteritinib can be decreased when combined with Norethisterone. |
| Norfloxacin | The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Gilteritinib. |
| Norgestimate | The serum concentration of Gilteritinib can be increased when it is combined with Norgestimate. |
| Nortriptyline | The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Gilteritinib. |
| Noscapine | The metabolism of Gilteritinib can be decreased when combined with Noscapine. |
| Octreotide | The metabolism of Gilteritinib can be decreased when combined with Octreotide. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Gilteritinib. |
| Olanzapine | The therapeutic efficacy of Olanzapine can be decreased when used in combination with Gilteritinib. |
| Olaparib | The metabolism of Olaparib can be decreased when combined with Gilteritinib. |
| Olodaterol | The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Gilteritinib. |
| Omadacycline | The serum concentration of Omadacycline can be increased when it is combined with Gilteritinib. |
| Ombitasvir | Gilteritinib may decrease the excretion rate of Ombitasvir which could result in a higher serum level. |
| Omeprazole | The metabolism of Gilteritinib can be increased when combined with Omeprazole. |
| Ondansetron | The therapeutic efficacy of Ondansetron can be decreased when used in combination with Gilteritinib. |
| Oritavancin | The metabolism of Gilteritinib can be increased when combined with Oritavancin. |
| Orphenadrine | The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Gilteritinib. |
| Osilodrostat | The metabolism of Gilteritinib can be decreased when combined with Osilodrostat. |
| Osimertinib | The metabolism of Osimertinib can be decreased when combined with Gilteritinib. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Gilteritinib. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Oxatomide. |
| Oxcarbazepine | The metabolism of Gilteritinib can be increased when combined with Oxcarbazepine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Oxybuprocaine. |
| Oxybutynin | The metabolism of Gilteritinib can be decreased when combined with Oxybutynin. |
| Oxytocin | The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gilteritinib. |
| Ozanimod | Gilteritinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. |
| Paclitaxel | The metabolism of Paclitaxel can be decreased when combined with Gilteritinib. |
| Pacritinib | The serum concentration of Gilteritinib can be increased when it is combined with Pacritinib. |
| Palbociclib | The metabolism of Palbociclib can be decreased when combined with Gilteritinib. |
| Paliperidone | The therapeutic efficacy of Paliperidone can be decreased when used in combination with Gilteritinib. |
| Palonosetron | The therapeutic efficacy of Palonosetron can be decreased when used in combination with Gilteritinib. |
| Pancuronium | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Pancuronium. |
| Panobinostat | The metabolism of Panobinostat can be decreased when combined with Gilteritinib. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Papaverine is combined with Gilteritinib. |
| Parathyroid | The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Gilteritinib. |
| Paritaprevir | The serum concentration of Gilteritinib can be increased when it is combined with Paritaprevir. |
| Paroxetine | The therapeutic efficacy of Paroxetine can be decreased when used in combination with Gilteritinib. |
| Pasireotide | The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Gilteritinib. |
| Pazopanib | The metabolism of Pazopanib can be decreased when combined with Gilteritinib. |
| Pefloxacin | The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Gilteritinib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Gilteritinib. |
| Penbutolol | The therapeutic efficacy of Penbutolol can be decreased when used in combination with Gilteritinib. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Gilteritinib. |
| Pentobarbital | The metabolism of Gilteritinib can be increased when combined with Pentobarbital. |
| Perampanel | The metabolism of Gilteritinib can be increased when combined with Perampanel. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Gilteritinib. |
| Pergolide | The therapeutic efficacy of Pergolide can be decreased when used in combination with Gilteritinib. |
| Perhexiline | The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Gilteritinib. |
| Pexidartinib | The metabolism of Pexidartinib can be decreased when combined with Gilteritinib. |
| Phenelzine | The therapeutic efficacy of Phenelzine can be decreased when used in combination with Gilteritinib. |
| Phenformin | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Phenformin. |
| Pheniramine | The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Gilteritinib. |
| Phenobarbital | The metabolism of Gilteritinib can be increased when combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Phenol. |
| Phenprocoumon | The metabolism of Phenprocoumon can be decreased when combined with Gilteritinib. |
| Phenylbutazone | The metabolism of Gilteritinib can be increased when combined with Phenylbutazone. |
| Phenytoin | The metabolism of Gilteritinib can be increased when combined with Phenytoin. |
| Pibrentasvir | Gilteritinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. |
| Pimavanserin | The therapeutic efficacy of Pimavanserin can be decreased when used in combination with Gilteritinib. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Pimozide. |
| Pinaverium | The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Gilteritinib. |
| Pindolol | The therapeutic efficacy of Pindolol can be decreased when used in combination with Gilteritinib. |
| Piperaquine | The metabolism of Gilteritinib can be decreased when combined with Piperaquine. |
| Pitavastatin | Gilteritinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level. |
| Pitolisant | The serum concentration of Gilteritinib can be decreased when it is combined with Pitolisant. |
| Pizotifen | The therapeutic efficacy of Pizotifen can be decreased when used in combination with Gilteritinib. |
| Pomalidomide | The metabolism of Pomalidomide can be decreased when combined with Gilteritinib. |
| Ponatinib | The metabolism of Ponatinib can be decreased when combined with Gilteritinib. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Gilteritinib. |
| Posaconazole | The metabolism of Gilteritinib can be decreased when combined with Posaconazole. |
| Potassium Iodide | The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Gilteritinib. |
| Potassium | The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Gilteritinib. |
| Pralatrexate | Gilteritinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
| Pralsetinib | Gilteritinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level. |
| Pramipexole | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Pramipexole. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Pramocaine. |
| Pravastatin | Gilteritinib may decrease the excretion rate of Pravastatin which could result in a higher serum level. |
| Prazosin | Gilteritinib may decrease the excretion rate of Prazosin which could result in a higher serum level. |
| Prednisolone | The metabolism of Gilteritinib can be increased when combined with Prednisolone. |
| Prednisolone | The metabolism of Gilteritinib can be increased when combined with Prednisolone acetate. |
| Prednisolone | The metabolism of Gilteritinib can be increased when combined with Prednisolone phosphate. |
| Prednisone acet | The metabolism of Gilteritinib can be increased when combined with Prednisone acetate. |
| Pregabalin | The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Gilteritinib. |
| Prenylamine | The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Gilteritinib. |
| Pretomanid | The metabolism of Gilteritinib can be decreased when combined with Pretomanid. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Prilocaine. |
| Primaquine | The risk or severity of QTc prolongation can be increased when Primaquine is combined with Gilteritinib. |
| Primidone | The metabolism of Gilteritinib can be increased when combined with Primidone. |
| Probenecid | The metabolism of Gilteritinib can be increased when combined with Probenecid. |
| Probucol | The risk or severity of QTc prolongation can be increased when Probucol is combined with Gilteritinib. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Procainamide. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Procaine. |
| Procarbazine | The therapeutic efficacy of Procarbazine can be decreased when used in combination with Gilteritinib. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Gilteritinib. |
| Promazine | The therapeutic efficacy of Promazine can be decreased when used in combination with Gilteritinib. |
| Promethazine | The therapeutic efficacy of Promethazine can be decreased when used in combination with Gilteritinib. |
| Propafenone | The risk or severity of QTc prolongation can be increased when Propafenone is combined with Gilteritinib. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Proparacaine. |
| Propiomazine | The therapeutic efficacy of Propiomazine can be decreased when used in combination with Gilteritinib. |
| Propofol | The risk or severity of QTc prolongation can be increased when Propofol is combined with Gilteritinib. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Propoxycaine. |
| Propylthiouracil | The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Gilteritinib. |
| Protirelin | The therapeutic efficacy of Protirelin can be decreased when used in combination with Gilteritinib. |
| Protriptyline | The therapeutic efficacy of Protriptyline can be decreased when used in combination with Gilteritinib. |
| Prucalopride | The therapeutic efficacy of Prucalopride can be decreased when used in combination with Gilteritinib. |
| Quetiapine | The therapeutic efficacy of Quetiapine can be decreased when used in combination with Gilteritinib. |
| Quinidine | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Quinidine. |
| Quinine | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Quinine. |
| Quinupristin | The metabolism of Gilteritinib can be decreased when combined with Quinupristin. |
| Raloxifene | Gilteritinib may decrease the excretion rate of Raloxifene which could result in a higher serum level. |
| Ranitidine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Ranitidine. |
| Ranolazine | The serum concentration of Gilteritinib can be increased when it is combined with Ranolazine. |
| Rasagiline | The therapeutic efficacy of Rasagiline can be decreased when used in combination with Gilteritinib. |
| Regorafenib | The metabolism of Regorafenib can be decreased when combined with Gilteritinib. |
| Relebactam | The excretion of Relebactam can be decreased when combined with Gilteritinib. |
| Relugolix | The serum concentration of Gilteritinib can be increased when it is combined with Relugolix. |
| Remdesivir | The metabolism of Gilteritinib can be decreased when combined with Remdesivir. |
| Reserpine | The serum concentration of Gilteritinib can be increased when it is combined with Reserpine. |
| Revefenacin | Gilteritinib may decrease the excretion rate of Revefenacin which could result in a higher serum level. |
| Ribociclib | The metabolism of Gilteritinib can be decreased when combined with Ribociclib. |
| Rifabutin | The metabolism of Gilteritinib can be increased when combined with Rifabutin. |
| Rifampicin | The metabolism of Gilteritinib can be increased when combined with Rifampicin. |
| Rifamycin | The metabolism of Gilteritinib can be increased when combined with Rifamycin. |
| Rifapentine | The metabolism of Gilteritinib can be increased when combined with Rifapentine. |
| Rilonacept | The metabolism of Gilteritinib can be increased when combined with Rilonacept. |
| Rilpivirine | The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Gilteritinib. |
| Riluzole | Gilteritinib may decrease the excretion rate of Riluzole which could result in a higher serum level. |
| Rimegepant | The serum concentration of Rimegepant can be increased when it is combined with Gilteritinib. |
| Riociguat | Gilteritinib may decrease the excretion rate of Riociguat which could result in a higher serum level. |
| Ripretinib | Gilteritinib may decrease the excretion rate of Ripretinib which could result in a higher serum level. |
| Risperidone | The therapeutic efficacy of Risperidone can be decreased when used in combination with Gilteritinib. |
| Ritonavir | The serum concentration of Gilteritinib can be increased when it is combined with Ritonavir. |
| Rivaroxaban | Gilteritinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. |
| Rizatriptan | The therapeutic efficacy of Rizatriptan can be decreased when used in combination with Gilteritinib. |
| Rocuronium | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Rocuronium. |
| Rofecoxib | The metabolism of Gilteritinib can be increased when combined with Rofecoxib. |
| Roflumilast | The metabolism of Gilteritinib can be decreased when combined with Roflumilast. |
| Rolapitant | The serum concentration of Gilteritinib can be increased when it is combined with Rolapitant. |
| Romidepsin | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Romidepsin. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Ropivacaine. |
| Rosoxacin | The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Gilteritinib. |
| Rosuvastatin | Gilteritinib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. |
| Rotigotine | The therapeutic efficacy of Rotigotine can be decreased when used in combination with Gilteritinib. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Gilteritinib. |
| Rucaparib | Gilteritinib may decrease the excretion rate of Rucaparib which could result in a higher serum level. |
| Rufinamide | The metabolism of Gilteritinib can be increased when combined with Rufinamide. |
| Rupatadine | The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Gilteritinib. |
| Ruxolitinib | The metabolism of Ruxolitinib can be decreased when combined with Gilteritinib. |
| Salbutamol | The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Gilteritinib. |
| Salmeterol | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Salmeterol. |
| Salmon calcitonin | The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Gilteritinib. |
| Sapropterin | The serum concentration of Gilteritinib can be increased when it is combined with Sapropterin. |
| Saquinavir | The metabolism of Gilteritinib can be decreased when combined with Saquinavir. |
| Sarecycline | The serum concentration of Gilteritinib can be increased when it is combined with Sarecycline. |
| Sarilumab | The metabolism of Gilteritinib can be increased when combined with Sarilumab. |
| Satralizumab | The serum concentration of Gilteritinib can be decreased when it is combined with Satralizumab. |
| Secobarbital | The metabolism of Gilteritinib can be increased when combined with Secobarbital. |
| Secukinumab | The metabolism of Gilteritinib can be increased when combined with Secukinumab. |
| Selegiline | The therapeutic efficacy of Selegiline can be decreased when used in combination with Gilteritinib. |
| Selexipag | The serum concentration of Gilteritinib can be increased when it is combined with Selexipag. |
| Selumetinib | Gilteritinib may decrease the excretion rate of Selumetinib which could result in a higher serum level. |
| Sertindole | The therapeutic efficacy of Sertindole can be decreased when used in combination with Gilteritinib. |
| Sertraline | The therapeutic efficacy of Sertraline can be decreased when used in combination with Gilteritinib. |
| Sevoflurane | The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Gilteritinib. |
| Sibutramine | The therapeutic efficacy of Sibutramine can be decreased when used in combination with Gilteritinib. |
| Sildenafil | The serum concentration of Gilteritinib can be increased when it is combined with Sildenafil. |
| Silodosin | The serum concentration of Gilteritinib can be increased when it is combined with Silodosin. |
| Siltuximab | The metabolism of Gilteritinib can be increased when combined with Siltuximab. |
| Simeprevir | The metabolism of Gilteritinib can be decreased when combined with Simeprevir. |
| Simvastatin | The serum concentration of Gilteritinib can be increased when it is combined with Simvastatin. |
| Siponimod | The metabolism of Siponimod can be decreased when combined with Gilteritinib. |
| Sirolimus | The metabolism of Sirolimus can be decreased when combined with Gilteritinib. |
| Sitagliptin | The serum concentration of Gilteritinib can be increased when it is combined with Sitagliptin. |
| Sitaxentan | The metabolism of Gilteritinib can be decreased when combined with Sitaxentan. |
| Sofosbuvir | Gilteritinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Gilteritinib. |
| Solriamfetol | The excretion of Solriamfetol can be decreased when combined with Gilteritinib. |
| Somatostatin | The metabolism of Gilteritinib can be decreased when combined with Somatostatin. |
| Somatrogon | The metabolism of Gilteritinib can be increased when combined with Somatrogon. |
| Sonidegib | The metabolism of Sonidegib can be decreased when combined with Gilteritinib. |
| Sorafenib | The metabolism of Sorafenib can be decreased when combined with Gilteritinib. |
| Sotagliflozin | The serum concentration of Gilteritinib can be increased when it is combined with Sotagliflozin. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Sotalol. |
| Sotorasib | The serum concentration of Gilteritinib can be decreased when it is combined with Sotorasib. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Sparfloxacin. |
| St. John’s Wort | The metabolism of Gilteritinib can be increased when combined with St. John’s Wort. |
| Stiripentol | The metabolism of Gilteritinib can be decreased when combined with Stiripentol. |
| Sulfamethoxazole | The metabolism of Gilteritinib can be decreased when combined with Sulfamethoxazole. |
| Sulfasalazine | Gilteritinib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level. |
| Sulfinpyrazone | The metabolism of Gilteritinib can be increased when combined with Sulfinpyrazone. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Gilteritinib. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Gilteritinib. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Sultopride. |
| Sumatriptan | The therapeutic efficacy of Sumatriptan can be decreased when used in combination with Gilteritinib. |
| Sunitinib | The metabolism of Sunitinib can be decreased when combined with Gilteritinib. |
| Suvorexant | The serum concentration of Gilteritinib can be increased when it is combined with Suvorexant. |
| Tacrolimus | The metabolism of Tacrolimus can be decreased when combined with Gilteritinib. |
| Talazoparib | Gilteritinib may decrease the excretion rate of Talazoparib which could result in a higher serum level. |
| Tamoxifen | The metabolism of Tamoxifen can be decreased when combined with Gilteritinib. |
| Tapentadol | The therapeutic efficacy of Tapentadol can be decreased when used in combination with Gilteritinib. |
| Tasimelteon | The metabolism of Gilteritinib can be decreased when combined with Tasimelteon. |
| Tazemetostat | Gilteritinib may decrease the excretion rate of Tazemetostat which could result in a higher serum level. |
| Technetium | The serum concentration of Gilteritinib can be increased when it is combined with Technetium Tc-99m sestamibi. |
| Tecovirimat | The metabolism of Gilteritinib can be increased when combined with Tecovirimat. |
| Tegaserod | The therapeutic efficacy of Tegaserod can be decreased when used in combination with Gilteritinib. |
| Telaprevir | The metabolism of Gilteritinib can be decreased when combined with Telaprevir. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Telavancin is combined with Gilteritinib. |
| Telithromycin | The metabolism of Gilteritinib can be decreased when combined with Telithromycin. |
| Telotristat ethyl | The serum concentration of Gilteritinib can be decreased when it is combined with Telotristat ethyl. |
| Temsirolimus | The metabolism of Temsirolimus can be decreased when combined with Gilteritinib. |
| Teniposide | The metabolism of Teniposide can be decreased when combined with Gilteritinib. |
| Tenofovir | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gilteritinib. |
| Tenofovir | The serum concentration of Gilteritinib can be increased when it is combined with Tenofovir disoproxil. |
| Tepotinib | The serum concentration of Gilteritinib can be increased when it is combined with Tepotinib. |
| Terbinafine | The metabolism of Gilteritinib can be increased when combined with Terbinafine. |
| Terbutaline | The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Gilteritinib. |
| Terfenadine | The metabolism of Gilteritinib can be decreased when combined with Terfenadine. |
| Teriflunomide | Gilteritinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level. |
| Teriparatide | The therapeutic efficacy of Teriparatide can be decreased when used in combination with Gilteritinib. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Gilteritinib. |
| Testosterone | Gilteritinib may decrease the excretion rate of Testosterone which could result in a higher serum level. |
| Testosterone | Gilteritinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. |
| Testosterone | Gilteritinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Tetrabenazine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Tetracaine. |
| Tetracycline | The metabolism of Gilteritinib can be decreased when combined with Tetracycline. |
| Tezacaftor | The serum concentration of Gilteritinib can be increased when it is combined with Tezacaftor. |
| Theophylline | The metabolism of Theophylline can be decreased when combined with Gilteritinib. |
| Thiamine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Thiamine. |
| Thiamylal | The metabolism of Gilteritinib can be increased when combined with Thiamylal. |
| Thioridazine | The therapeutic efficacy of Thioridazine can be decreased when used in combination with Gilteritinib. |
| Thiotepa | The metabolism of Thiotepa can be decreased when combined with Gilteritinib. |
| Thiothixene | The therapeutic efficacy of Thiothixene can be decreased when used in combination with Gilteritinib. |
| Thyroid, porcine | The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Gilteritinib. |
| Thyrotropin alfa | The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Gilteritinib. |
| Ticagrelor | The serum concentration of Gilteritinib can be increased when it is combined with Ticagrelor. |
| Timolol | The risk or severity of QTc prolongation can be increased when Timolol is combined with Gilteritinib. |
| Tipranavir | The metabolism of Gilteritinib can be decreased when combined with Tipranavir. |
| Tivozanib | The serum concentration of Gilteritinib can be increased when it is combined with Tivozanib. |
| Tizanidine | The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Gilteritinib. |
| Tocilizumab | The metabolism of Gilteritinib can be increased when combined with Tocilizumab. |
| Tolterodine | The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Gilteritinib. |
| Tolvaptan | The metabolism of Tolvaptan can be decreased when combined with Gilteritinib. |
| Topiramate | The metabolism of Gilteritinib can be increased when combined with Topiramate. |
| Topotecan | The excretion of Topotecan can be decreased when combined with Gilteritinib. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Toremifene. |
| Trabectedin | The metabolism of Trabectedin can be decreased when combined with Gilteritinib. |
| Tramadol | The therapeutic efficacy of Tramadol can be decreased when used in combination with Gilteritinib. |
| Tranylcypromine | The therapeutic efficacy of Tranylcypromine can be decreased when used in combination with Gilteritinib. |
| Trastuzumab | The metabolism of Trastuzumab emtansine can be decreased when combined with Gilteritinib. |
| Trazodone | The therapeutic efficacy of Trazodone can be decreased when used in combination with Gilteritinib. |
| Treprostinil | The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Gilteritinib. |
| Triamcinolone | The metabolism of Gilteritinib can be increased when combined with Triamcinolone. |
| Triclabendazole | The metabolism of Gilteritinib can be decreased when combined with Triclabendazole. |
| Triflupromazine | The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Gilteritinib. |
| Trilaciclib | Gilteritinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Gilteritinib. |
| Trimethadione | The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Gilteritinib. |
| Trimipramine | The therapeutic efficacy of Trimipramine can be decreased when used in combination with Gilteritinib. |
| Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Gilteritinib. |
| Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Gilteritinib. |
| Troglitazone | The metabolism of Gilteritinib can be increased when combined with Troglitazone. |
| Troleandomycin | The metabolism of Gilteritinib can be decreased when combined with Troleandomycin. |
| Tropisetron | The therapeutic efficacy of Tropisetron can be decreased when used in combination with Gilteritinib. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Trovafloxacin. |
| Tubocurarine | The risk or severity of adverse effects can be increased when Gilteritinib is combined with Tubocurarine. |
| Tucatinib | Tucatinib may decrease the excretion rate of Gilteritinib which could result in a higher serum level. |
| Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Gilteritinib. |
| Umbralisib | The serum concentration of Gilteritinib can be increased when it is combined with Umbralisib. |
| Valproic acid | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Valproic acid. |
| Vandetanib | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Vandetanib. |
| Vardenafil | The serum concentration of Gilteritinib can be increased when it is combined with Vardenafil. |
| Velpatasvir | Gilteritinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Vemurafenib | The serum concentration of Gilteritinib can be increased when it is combined with Vemurafenib. |
| Venetoclax | The metabolism of Venetoclax can be decreased when combined with Gilteritinib. |
| Venlafaxine | The therapeutic efficacy of Venlafaxine can be decreased when used in combination with Gilteritinib. |
| Verapamil | The metabolism of Gilteritinib can be decreased when combined with Verapamil. |
| Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Gilteritinib. |
| Vilanterol | The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Gilteritinib. |
| Vilazodone | The therapeutic efficacy of Vilazodone can be decreased when used in combination with Gilteritinib. |
| Viloxazine | The metabolism of Gilteritinib can be decreased when combined with Viloxazine. |
| Vinblastine | The metabolism of Vinblastine can be decreased when combined with Gilteritinib. |
| Vincristine | The metabolism of Vincristine can be decreased when combined with Gilteritinib. |
| Vindesine | The metabolism of Vindesine can be decreased when combined with Gilteritinib. |
| Vinflunine | The metabolism of Vinflunine can be decreased when combined with Gilteritinib. |
| Vinorelbine | The metabolism of Vinorelbine can be decreased when combined with Gilteritinib. |
| Vitamin E | The metabolism of Gilteritinib can be increased when combined with Vitamin E. |
| Voclosporin | The serum concentration of Gilteritinib can be increased when it is combined with Voclosporin. |
| Vorapaxar | The serum concentration of Gilteritinib can be increased when it is combined with Vorapaxar. |
| Voriconazole | The serum concentration of Gilteritinib can be increased when it is combined with Voriconazole. |
| Vorinostat | The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Gilteritinib. |
| Vortioxetine | The therapeutic efficacy of Vortioxetine can be decreased when used in combination with Gilteritinib. |
| Voxilaprevir | Gilteritinib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Warfarin | The metabolism of Warfarin can be decreased when combined with Gilteritinib. |
| Yohimbine | The therapeutic efficacy of Yohimbine can be decreased when used in combination with Gilteritinib. |
| Zafirlukast | The metabolism of Gilteritinib can be decreased when combined with Zafirlukast. |
| Zanubrutinib | The metabolism of Zanubrutinib can be decreased when combined with Gilteritinib. |
| Zidovudine | Gilteritinib may decrease the excretion rate of Zidovudine which could result in a higher serum level. |
| Zimelidine | The therapeutic efficacy of Zimelidine can be decreased when used in combination with Gilteritinib. |
| Ziprasidone | The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Gilteritinib. |
| Zolmitriptan | The therapeutic efficacy of Zolmitriptan can be decreased when used in combination with Gilteritinib. |
| Zonisamide | The serum concentration of Gilteritinib can be increased when it is combined with Zonisamide. |
| Zotepine | The therapeutic efficacy of Zotepine can be decreased when used in combination with Gilteritinib. |
| Zuclopenthixol | The therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Gilteritinib. |
Drug-Food Interactions
- Avoid grapefruit products. Grapefruit inhibits CYP3A metabolism, which may increase the serum concentration of gilteritinib.
- Avoid St. John’s Wort. This herb induces CYP3A4 and p-glycoprotein, which may reduce the serum concentration of gilteritinib.
- Take it at the same time every day.
- Take it with or without food.
Pregnancy and Lactation
US FDA pregnancy category Not Assigned
Pregnancy
This medication should not be used during pregnancy due to the risk that it may cause harm to the unborn baby. If you become pregnant while taking this medication, contact your doctor immediately.
Lactation
It is not known if gilteritinib passes into breast milk. If you are breast-feeding and are taking this medication, it may affect your baby. Women are advised to avoid breastfeeding while taking this medication and for 2 months after taking the last dose.
How should this medicine be used?
Gilteritinib comes as a tablet to take by mouth. It is usually taken once daily with or without food for at least 6 months. Take gilteritinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take gilteritinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the tablets whole with water; do not split, chew, or crush them.
Your doctor may adjust your dose or temporarily or permanently stop your treatment depending on how well the medication works for you and if you experience any side effects. Talk to your doctor about how you are feeling during your treatment. Continue to take gilteritinib even if you feel well. Do not stop taking gilteritinib without talking to your doctor.
What special precautions should I follow?
Before taking gilteritinib,
- tell your doctor and pharmacist if you are allergic to gilteritinib, any other medications, or any of the ingredients in gilteritinib tablets. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: certain antifungals such as fluconazole (Diflucan), itraconazole (Onmel, Sporanox), and ketoconazole; clarithromycin (Biaxin, in PrevPac); escitalopram (Lexapro); fluoxetine (Prozac); certain medications for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra), and saquinavir (Invirase); certain medications for seizures such as carbamazepine (Carbatrol, Epitol, Tegretol, others), phenobarbital, and phenytoin (Dilantin, Phenytek); nefazodone; pioglitazone (Actos); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, in Rifamate, in Rifater); and sertraline (Zoloft). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with gilteritinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor what herbal products you are taking, especially St. John’s wort.
- tell your doctor if you have or have ever had a QT interval prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death); a slow, fast, or irregular heartbeat; or low levels of potassium or magnesium in your blood.
- tell your doctor if you are pregnant, plan to become pregnant, or if you plan to father a child. You or your partner should not become pregnant while you are taking gilteritinib. If you are female, you will need to have a pregnancy test at least 7 days before you start treatment, and you should use birth control during your treatment and for 6 months after your final dose. If you are male, you and your partner should use birth control to prevent pregnancy during your treatment and for 4 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while taking gilteritinib, call your doctor. Gilteritinib may harm the fetus.
- tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with gilteritinib and for 2 months after your final dose.
References
